ArticleCytotechnology2025
Cell-based evaluation of anti-inflammatory activity from the combination of natural compounds in LPS-stimulated U937 monocytes.
Article in Cytotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Production optimization andFrontiers in microbiology · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The present study aims to examine the potential effects of a novel coupling of natural-derived compounds modulating inflammatory responses. Their effects were assessed in LPS-inflamed U937 pro-monocytes. Monocytes were exposed to incremental concentrations of citric acid (2-hydroxy-1, 2, 3-propanetricarboxylic acid) and quercetin (3, 3', 4', 5, 7-pentahydroxyflavone), administered individually and in combination. Evaluation of cell viability was conducted via the MTT assay; nitric oxide (NO) production was assessed using the Griess assay; the expression levels of key pro-inflammatory markers (IL-1β, IL-6, TNF-α, and COX-2) were determined through quantitative real-time PCR (qRT-PCR). The results indicate that the two combined substances modulate the pathways of anti-inflammatory cytokines in pro-monocytic cells. Collectively, our data indicated that the synergistic activity of quercetin and citric acid has the potential to be developed as a novel therapeutic agent for inflammatory-related diseases, also opening new avenues for developing natural strategies in pathologies related to inflammatory processes treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.